A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease
This study has been completed.
First Posted: January 31, 2006
Last Update Posted: April 15, 2015
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||May 2008|
|Primary Completion Date:||May 2008 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||August 17, 2010|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, Barisoni L, Jennette CJ, Bragat A, Castelli J, Sitaraman S, Lockhart DJ, Boudes PF. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012 Nov 24;7:91. doi: 10.1186/1750-1172-7-91.